The IMS Institute for Healthcare Informatics worked up a methodology for assessing the effectiveness of pharma’s social media efforts across Facebook, Twitter and YouTube.
The IMS Institute for Healthcare Informatics worked up a methodology for assessing the effectiveness of pharma’s social media efforts across Facebook, Twitter and YouTube, according to three indices: reach (total number of people reached through each channel via likes, shares and re-tweets); relevance (extent to which content is being shared and forwarded); and relationship (amount of back and forth between company and patient).
Those pharmas hitting the trifecta scored best on the cumulative “Social Media Engagement Index.” Results were tallied over a two-year period. Here are the top ten pharma engagers, per IMS Health. To read the full report, which discusses the role of Wikipedia, healthcare professionals’ use of social media, and a summary of social media regulatory policy in the US, Canada and the EU, click here. And the winners are:
IMS Health Social Engagement Index
1. Johnson & Johnson
2. GlaxoSmithKline
3.Novo Nordisk
4. Pfizer
5. Novartis
6. Boehringer Ingelheim
7. Bayer
8. Merck
9. AstraZeneca
10. UCB
In a separate article, consultants at Capgemini Consulting Life Sciences wonder if social media in pharma has reached a tipping point. PharmExec’s sibling company, CBI, is hosting its annual iPharma conference in New York City this May.
The Weight-Loss Gold Rush: Legal and Regulatory Implications
July 11th 2024Jim Shehan, chair of the FDA Regulatory practice, Lowenstein Sandler, discusses how the FDA and other regulators likely to respond to the increased public interest and potential off-label use of GLP-1 drugs, what needs to be done for GLP-1s to be covered, advice for investors and financiers considering entering the weight-loss medication market and more.
Healthcare Marketing Strategies for Reaching Diverse Audiences
May 14th 2024Amanda Powers-Han, Chief Marketing Officer, Greater Than One, and Pharmaceutical Executive Editorial Advisory Board member, discusses how improved DE&I in healthcare marketing strategies can not only reach diverse audiences more effectively but also contribute to improved patient care outcomes, challenges faced in crafting culturally sensitive messages, and much more.
The Weight-Loss Gold Rush: Legal and Regulatory Implications
July 11th 2024Jim Shehan, chair of the FDA Regulatory practice, Lowenstein Sandler, discusses how the FDA and other regulators likely to respond to the increased public interest and potential off-label use of GLP-1 drugs, what needs to be done for GLP-1s to be covered, advice for investors and financiers considering entering the weight-loss medication market and more.
Healthcare Marketing Strategies for Reaching Diverse Audiences
May 14th 2024Amanda Powers-Han, Chief Marketing Officer, Greater Than One, and Pharmaceutical Executive Editorial Advisory Board member, discusses how improved DE&I in healthcare marketing strategies can not only reach diverse audiences more effectively but also contribute to improved patient care outcomes, challenges faced in crafting culturally sensitive messages, and much more.
2 Commerce Drive
Cranbury, NJ 08512